Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 29, 2023

Effects of Canagliflozin on the Outcomes of Patients With Type 2 Diabetes in Subgroups of Population-Specific BMI

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial
Diabetes Obes Metab 2023 Sep 06;[EPub Ahead of Print], J Yu, AN Sweeting, C Gianacas, L Houston, V Lee, RA Fletcher, V Perkovic, Q Li, BL Neuen, O Berwanger, HJL Heerspink, D de Zeeuw, C Arnott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading